Association of White Blood Cell Count with Treatment Response to Cefepime vs Piperacillin-Tazobactam
Listen to this summary
The authors aimed to investigate whether white blood cell (WBC) count influences the relationship between antibiotic choice (cefepime vs. piperacillin-tazobactam) and mortality in sepsis treatment. Their analysis of data from the ACORN trial and an Instrumental Variable study revealed that WBC count significantly modified the effect of antibiotic choice on 28-day mortality, suggesting that higher baseline WBC counts were associated with better outcomes when treated with piperacillin-tazobactam. The findings indicate a need for further research to explore the potential of WBC count as a predictive marker in future studies of anti-pseudomonal antibiotics.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from American journal of respiratory and critical care medicine
View all →Jun 12, 2026 · American journal of respiratory and critical care medicine
Defining disease stability in COPD: Evidence from Phase 3 clinical trials
Jun 11, 2026 · American journal of respiratory and critical care medicine
Identification of Pulmonary Arterial Hypertension Patients with Venous or Capillary Involvement
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
